126 related articles for article (PubMed ID: 6809500)
1. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
2. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
3. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
7. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
8. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
10. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
Baumann R; Kuhl H; Taubert HD; Sandow J
Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
[TBL] [Abstract][Full Text] [Related]
11. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
13. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
[TBL] [Abstract][Full Text] [Related]
15. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
Bergquist C; Nillius SJ; Wide L
Ups J Med Sci; 1984; 89(2):99-106. PubMed ID: 6431676
[TBL] [Abstract][Full Text] [Related]
16. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
[TBL] [Abstract][Full Text] [Related]
17. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
Gudmundsson JA; Lundkvist O; Bergquist C; Lindgren A; Nillius SJ
Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
[TBL] [Abstract][Full Text] [Related]
18. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
19. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
20. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
Bergquist C; Nillius SJ; Wide L
Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
